Maury Philippe, Audoubert Mathieu, Cintas Pascal, Rollin Anne, Duparc Alexandre, Mondoly Pierre, Chiriac Ana-Maria, Acket Blandine, Zhao Xinran, Pasquié Jean Luc, Cardin Christelle, Delay Marc, Sadron Marie, Carrié Didier, Galinier Michel, Davy Jean-Marc, Arne-Bès Marie-Christine, Raczka Franck
Department of Cardiology, University Hospital Rangueil Toulouse, France.
Department of Cardiology, University Hospital Rangueil Toulouse, France.
Heart Rhythm. 2014 Oct;11(10):1721-7. doi: 10.1016/j.hrthm.2014.07.011. Epub 2014 Jul 9.
Both type 1 myotonic dystrophy (MD1) and Brugada syndrome (BrS) may be complicated by conduction disturbances and sudden death. Spontaneous BrS has been observed in MD1 patients, but the prevalence of drug-induced BrS in MD1 is unknown.
The purpose of this study was to prospectively assess the prevalence of type 1 ST elevation as elicited during pharmacologic challenge with Class 1C drugs in a subgroup of MD1 patients and to further establish correlations with ECG and electrophysiologic variables and prognosis.
From a group of unselected 270 MD1 patients, ajmaline or flecainide drug challenge was performed in a subgroup of 44 patients (27 men, median age 43 years) with minor depolarization/repolarization abnormalities suggestive of possible BrS. The presence of type 1 ST elevation after drug challenge was correlated to clinical, ECG, and electrophysiologic variables.
Eight of 44 patients (18%) presented with BrS after drug challenge. BrS was seen more often in men (26% vs 6%, P = .09) and was related to younger age (35 vs 48 years, P = .07). BrS was not correlated to symptoms, baseline ECG, HV interval, results of signal-averaged ECG, or abnormalities on ambulatory recordings. MD1 patients with BrS had longer corrected QT intervals, greater increase in PR interval after drug challenge, and higher rate of inducible ventricular arrhythmias (62% vs 21%, P = .03). Twelve patients were implanted with a pacemaker and 5 with an implantable cardioverter-defibrillator. Significant bradycardia did not occur in any patients, and malignant ventricular arrhythmia never occurred during median 7-year follow-up (except 1 hypokalemia-related ventricular fibrillation).
BrS is elicited by a Class 1 drug in 18% of MD1 patients presenting with minor depolarization/repolarization abnormalities at baseline, but the finding seems to be devoid of a prognostic role.
1型强直性肌营养不良(MD1)和 Brugada 综合征(BrS)均可并发传导障碍和猝死。MD1 患者中已观察到自发性 BrS,但 MD1 中药物诱导性 BrS 的患病率尚不清楚。
本研究的目的是前瞻性评估一组 MD1 患者在使用 1C 类药物进行药物激发试验期间诱发的 1 型 ST 段抬高的患病率,并进一步建立其与心电图和电生理变量及预后的相关性。
在一组未经选择的 270 例 MD1 患者中,对 44 例(27 例男性,中位年龄 43 岁)有轻微去极化/复极化异常提示可能为 BrS 的患者进行了阿义马林或氟卡尼药物激发试验。药物激发试验后 1 型 ST 段抬高的出现与临床、心电图和电生理变量相关。
44 例患者中有 8 例(18%)在药物激发试验后出现 BrS。BrS 在男性中更常见(26%对 6%,P = 0.09),且与年龄较轻有关(35 岁对 48 岁,P = 0.07)。BrS 与症状、基线心电图、HV 间期、信号平均心电图结果或动态记录异常无关。患有 BrS 的 MD1 患者校正 QT 间期更长,药物激发试验后 PR 间期增加更大,可诱导性室性心律失常发生率更高(62%对 21%,P = 0.03)。12 例患者植入了起搏器,5 例植入了植入式心脏复律除颤器。在中位 7 年随访期间,没有患者发生显著心动过缓,也从未发生恶性室性心律失常(1 例与低钾血症相关的心室颤动除外)。
在基线时有轻微去极化/复极化异常的 MD1 患者中,18%的患者在使用 1 类药物后诱发 BrS,但这一发现似乎没有预后意义。